# US 2024/0197744 A1 · Treating sex steroid dependent cancer with bmx inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197744 A1
- Document ID: US20240197744A1
- Status: Published application
- Kind: A1
- Application number: 18/557,011
- Filed: 2022-05-10
- Published: 2024-06-20
- Earliest claimed: 2021-05-12
- Assignees: The Cleveland Clinic Foundation
- Applicants: The Cleveland Clinic Foundation
- Inventors: Nima SHARIFI
- Web page: https://patentgrep.com/patent/US20240197744A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/04: specific for metastasis
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61P 35/00: Antineoplastic agents
- C07K 16/40: against enzymes
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/904: acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods, kits, and compositions for treating sex steroid dependent cancer using BMX inhibitors. In certain embodiments, a sample from a subject having, or suspected of having, a sex steroid dependent disease cancer, is further assayed to determine: i) if the subject is heterozygous or homozygous for the HSD3B1(1245C) allele that encodes for the 3βSD1(367T) protein. In some embodiments, the BMX inhibitor comprises a monoclonal antibody or BMX binding portion thereof (e.g., zanubrutinib, acalabrutinib, abivertinib or ibrutinib).

## Claims

### Claim 1

A method of treating sex steroid dependent cancer comprising:
treating a subject having a sex steroid dependent cancer with a cytoplasmic tyrosine-protein kinase BMX (BMX) inhibitor.

### Claim 2 (depends on 1)

The method claim 1, wherein said sex steroid dependent cancer is selected from the group consisting of: prostate cancer, breast cancer, ovarian cancer, and endometrial cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein said BMX inhibitor comprises an anti-BMX monoclonal antibody or BMX binding portion thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein said BMX inhibitor comprises zanubrutinib.

### Claim 5 (depends on 1)

The method of claim 1, wherein said BMX inhibitor comprises acalabrutinib.

### Claim 6 (depends on 1)

The method of claim 1, wherein said subject is 367T in the3βHSD1 protein.

### Claim 7 (depends on 1)

The method of claim 1, further comprising conducting an assay on a sample from said subject to determine if said subject is 367T or 367N in their 3βHSD1 protein.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject is heterozygous or homozygous for 1245C in the HSD3B1 gene.

### Claim 9 (depends on 1)

The method of claim 1, further comprising conducting an assay on a sample from said subject to determine if said subject is heterozygous or homozygous for 1245C in the HSD3B1 gene.

### Claim 10 (depends on 1)

The method of claim 1, wherein said subject is a human.

### Claim 11

An in vitro composition comprising:
a) human sex steroid dependent cancer cells; and
b) a BMX inhibitor that is exogenous to said human sex steroid cancer cells.

### Claim 12 (depends on 11)

The in vitro composition of claim 11, wherein said BMX inhibitor comprises an anti-BMX monoclonal antibody or BMX binding portion thereof.

### Claim 13 (depends on 11)

The in vitro composition of claim 11, wherein said BMX inhibitor comprises zanubrutinib.

### Claim 14 (depends on 11)

The in vitro composition of claim 11, wherein said BMX inhibitor comprises acalabrutinib.

### Claim 15 (depends on 11)

The in vitro composition of claim 11, wherein said human sex steroid cancer cells comprise prostate cancer cells.

### Claim 16 (depends on 1)

The in vitro composition of claim 1, wherein said prostate cancer cells are 367T in the3βHSD1 protein.

### Claim 17 (depends on 1)

The in vitro composition of claim 1, wherein said sex steroid dependent cancer cells are heterozygous or homozygous for 1245C in the HSD3B1 gene.

### Claim 18 (depends on 11)

The in vitro composition of claim 11, wherein said human sex steroid dependent cancer cells are breast cancer cells.

### Claim 19 (depends on 11)

The in vitro composition of claim 11, wherein said human sex steroid dependent cancer cells are ovarian cancer cells.

### Claim 20 (depends on 11)

The in vitro composition of claim 11, wherein said human sex steroid dependent cancer cells are endometrial cancer cells.
